Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study

References

• Ogihara T Kikuchi K Matsuoka H Japanese Society of Hypertension Committee The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) Hypertens Res 2009 32 1 3 107 19300436
   PubMed Web of Science ®Google Scholar
• Katayama S Inaba M Morita T Awata T Shimamoto K Kikkawa R Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus Hypertens Res 2000 23 6 601 605 11131272
   PubMed Web of Science ®Google Scholar
• Kiya Y Miura S Fujino M Imaizumi S Karnik SS Saku K Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan Clin Exp Hypertens 2010 32 2 129 136 20374187
   PubMed Web of Science ®Google Scholar
• Oparil S Williams D Chrysant SG Marbury TC Neutel J Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension J Clin Hypertens (Greenwich) 2001 3 5 283 291 11588406
   PubMedGoogle Scholar
• Brunner HR Stumpe KO Januszewicz A Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension Clin Drug Investig 2003 23 7 419 430
   PubMed Web of Science ®Google Scholar
• Saito I Kario K Kushiro T Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study Hypertens Res 2013 36 2 177 182 23096234
   PubMed Web of Science ®Google Scholar
• Li P Koike T Jiang HY Wang ZH Kawata Y Oshida Y Acute treatment with candesartan cilexetil, an angiotensin II type 1 receptor blocker, improves insulin sensitivity in high-fructose-diet-fed rats Horm Metab Res 2012 44 4 286 290 22344624
   PubMed Web of Science ®Google Scholar
• Benson SC Pershadsingh HA Ho CI Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity Hypertension 2004 43 5 993 1002 15007034
   PubMed Web of Science ®Google Scholar
• Sezai A Soma M Hata M Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery – investigation using a candesartan change-over study Ann Thorac Cardiovasc Surg 2011 17 5 487 493 21881353
   PubMed Web of Science ®Google Scholar
• Furukawa T Hatsuno T Ueno Y Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil Clin Drug Investig 2009 29 4 257 264
   Web of Science ®Google Scholar
• Nakayama S Watada H Mita T Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension Hypertens Res 2008 31 1 7 13 18360012
   PubMed Web of Science ®Google Scholar
• Ikeda H Hamamoto Y Honjo S Nabe K Wada Y Koshiyama H Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes Diabetes Res Clin Pract 2009 83 1 117 118 19062123
   PubMed Web of Science ®Google Scholar
• Fukuda M Yamanaka T Mizuno M Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis J Hypertens 2008 26 3 583 588 18300871
   PubMed Web of Science ®Google Scholar
• Shimada K Ogihara T Saruta T Kuramoto K REZALT Study Group Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study Clin Ther 2010 32 5 861 881 20685495
   PubMed Web of Science ®Google Scholar
• Kario K Hoshide S Shimizu M Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study J Hypertens 2010 28 7 1574 1583 20404743
   PubMed Web of Science ®Google Scholar
• Mori H Yamamoto H Ukai H COMPATIBLE Study Group Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study Hypertens Res 2013 36 3 202 207 23013888
   PubMed Web of Science ®Google Scholar
• Daikuhara H Kikuchi F Ishida T The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study Diab Vasc Dis Res 2012 9 4 280 286 22718810
   PubMed Web of Science ®Google Scholar
• Nakanishi K Nagai Y Piao H Changes in renal vessels following the long-term administration of an angiotensin II receptor blocker in Zucker fatty rats J Renin Angiotensin Aldosterone Syst 2011 12 2 65 74 21385769
   PubMed Web of Science ®Google Scholar
• Mancia G Fagard R Narkiewicz K Task Force Members 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 2013 31 7 1281 1357 23817082
   PubMed Web of Science ®Google Scholar
• Yusuf S Teo KK Pogue J ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 2008 358 15 1547 1559 18378520
   PubMed Web of Science ®Google Scholar